Reading BKYI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BKYI free→Reading BKYI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BKYI free→IndustrialsSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Peer multiples imply a price about 123% below where it trades (it looks expensive on this basis); the read is rich. The outlook hinges on sector trends, particularly if bellwethers like BA, CAT, and UNP continue to perform well. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $4.16. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $4.16 BKYI trades at 1× p/s, below its 2× p/s peer median. Our $6.47 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 123% near-term growth, well above our forecast of about -7%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Industrials names rated weak grew net income 58% of the time over the next year (vs 62% for the rest of the cohort, n=3678).
Over the trailing year it converted 0.65x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
12 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Industrials names rated volatile grew net income 59% of the time over the next year (vs 59% for the rest of the cohort, n=840).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLI
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$282.
How much price usually moves either way.
On a bad day, this stock has moved -$793.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,641.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'expensive' to 'inexpensive'.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for BKYI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 5, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the Listings Qualifications Department of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 with the U.S. Securities and Exchange Commission (the “ SEC ”) as required by Nasdaq Listing Rule 5250(c)(1) (the “…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2013-Q1, 2013-Q2, 2013-Q3, 2014-Q2
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
BKYI BIO-KEY INTERNATIONAL INC | Below typical Show detailsSector percentile: 12 of 100 | inexpensive | high |
Not investment advice. As of 2026-06-16.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
No qualifying priorities for this snapshot. Check back after the next refresh.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Rule ”), as the Company’s closing bid price was not at least $1.00 per share for 10 consecutive business days as of May 4, 2026. As a result, the Compan…
Results of Operations and Financial Condition. On May 18, 2026 BIO-key International, Inc. (the “Company”) issued a press release announcing its financial results for its first quarter 2026. A copy of the press release issued by the Company on May 18, 2026 is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange A…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 16, 2026, BIO-key International, Inc. (the “ Company ”) received notice from The Nasdaq Stock Market, LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company’s failure to timely file its Annual Report…
Results of Operations and Financial Condition. On April 16, 2026, BIO-key International, Inc. (the “Company”) issued a press release which included information about its results of operations for its first quarter ended March 31, 2026. A copy of the press release issued by the Company on April 16, 2026 is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Ex…